← Back to Fundingfunding

Aneuvo raises $22M Series C for ECAP-sensing spinal cord stimulation — ExaStim heads to FDA

Aneuvo closed a $22 million Series C in March 2026 for ExaStim, an ECAP-sensing spinal cord stimulation system for chronic pain. FDA 510(k) submitted May 2026.

Body Mind StateAugust 17, 20265 min read
Aneuvo raises $22M Series C for ECAP-sensing spinal cord stimulation — ExaStim heads to FDA

The Raise

Aneuvo closed a $22 million Series C in March 2026, led by Novo Holdings.

What They're Building

Aneuvo is developing ExaStim, a next-generation spinal cord stimulation (SCS) system for chronic back and leg pain. Unlike conventional SCS, ExaStim uses evoked compound action potential (ECAP) sensing to measure the spinal cord's real-time response and adjust stimulation automatically.

FDA Status

Aneuvo submitted the ExaStim system for FDA 510(k) clearance in May 2026.

Why This Matters

Spinal cord stimulation has been criticized for poor long-term outcomes. ECAP-controlled SCS directly addresses one of the primary failure modes: fixed stimulation that doesn't adapt.

Related

Aurenar raises $5.7M seed to bring vagus nerve stimulation into the ICU for inflammation
funding

Aurenar raises $5.7M seed to bring vagus nerve stimulation into the ICU for inflammation

Aurenar closed an oversubscribed $5.7 million seed round in July 2026 to advance V-Link, a non-invasive taVNS device for ICU inflammation. FDA Breakthrough Device designation granted June 2026.

Aug 17, 20264 min read
Nervonik closes $52.5M Series B for closed-loop peripheral nerve stimulation for chronic pain
funding

Nervonik closes $52.5M Series B for closed-loop peripheral nerve stimulation for chronic pain

Nervonik closed an oversubscribed $52.5 million Series B in April 2026 for its miniaturized, wireless, closed-loop peripheral nerve stimulation platform for chronic neuropathic pain.

Aug 17, 20264 min read
Neurotech funding hits $2.64 billion in H1 2026 — a landscape view
funding

Neurotech funding hits $2.64 billion in H1 2026 — a landscape view

Neurotechnology companies raised approximately $2.64 billion in H1 2026, a 31% increase over H1 2025. Key raises include Setpoint Medical ($115M), Nervonik ($52.5M), Aneuvo ($22M), and Aurenar ($5.7M).

Aug 17, 20266 min read

Stay Regulated

Regulate your nervous system from the inside out.

New research, honest product reviews, neurotech funding rounds, and events — delivered weekly, with zero sponsors or ads.